Tech Company Financing Transactions
Alida Biosciences Funding Round
Genoa Ventures, FusionX Ventures and Vertical Venture Partners participated in a $7.5 million Series A venture round for Alida Biosciences. The round was announced on 6/12/2024.
Transaction Overview
Company Name
Announced On
6/12/2024
Transaction Type
Venture Equity
Amount
$7,500,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to further enhance its product development, as well as to bring the EpiPlex kit to markets.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
11535 Sorrento Valley Rd. 407
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Undisclosed
Website
Email Address
Overview
Alida Bio is pioneering technology for next-generation epigenetic analysis that will empower a new wave of research, therapeutics, and diagnostics. Epigenetic markers, including modifications of DNA, RNA and histone proteins, work in concert to control how the genetic code is used in health and disease. Unlike current methods that detect single modifications one at a time, our technology accurately detects and locates many epigenetic markers simultaneously.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gudrun Stengel
Co-Founder
Byron Purse
VP - Engineering
Zachary Miles
VP - R & D
Andrew Price
Browse more venture capital transactions:
Prev: 6/12/2024: Alzheon venture capital transaction
Next: 6/12/2024: Tern AI venture capital transaction
Share this article
Where The Data Comes From
We document all VC transactions involving tech companies. VC investment data records on this site are derived from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs